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Self-report sleep quality combined with sleep time
variability distinguishes differences in fatigue,
anxiety, and depression in individuals with
multiple sclerosis: A secondary analysis
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Abstract
Background: Nearly 70% of individuals with multiple sclerosis report sleep disturbances or poor sleep
quality. Sleep disturbances may exacerbate or complicate the management of multiple sclerosis-related
symptoms. While sleep variability has been associated with several health outcomes, it is unclear how
sleep variability is associated with multiple sclerosis-related symptoms.
Objective: The purpose of this study was to determine how total sleep time variability combined with
self-reported sleep quality is associated with fatigue, depression, and anxiety in individuals with mul-
tiple sclerosis.
Methods: This study involved a secondary analysis of actigraphy data and questionnaires to assess sleep
quality, fatigue, anxiety, and depression.
Results: There were significant differences between the Good Sleepers (good sleep quality/low sleep
time variability; n¼14) and Bad Sleepers (poor sleep quality/high sleep time variability; n¼23) in
overall fatigue (p¼0.003), cognitive (p¼0.002) and psychosocial fatigue (p¼0.01) subscales, and in
trait anxiety (p¼0.007). There were significant differences in state (p¼0.004) and trait (p¼0.001) anx-
iety and depression (p¼0.002) between the Good Sleepers and Poor Reported Sleepers (poor sleep
quality/low sleep time variability; n¼24).
Conclusion: These results indicate different factors are associated with poor sleep quality in individuals
with low versus high total sleep time variability. Considering the factors that are associated with sleep
quality and variability may allow for better tailoring of interventions aimed at improving sleep issues or
comorbid conditions.
Keywords: Sleep quality, sleep variability, multiple sclerosis, fatigue, anxiety, depression
Date received: 24 August 2018; Revised received 29 October 2018; accepted: 6 November 2018
Introduction
Studies have found that nearly 70% of individuals
with multiple sclerosis (MS) report sleep disturban-
ces or poor sleep quality.1,2 Sleep disturbances
in individuals with MS can be caused by the disease
itself (if demyelination affects the suprachiasmatic
nucleus)3 or by secondary factors often experienced
by individuals with MS (such as spasticity, anxiety,
stress, depression, and nocturia).4–6 While
approximately 50% of individuals with MS have
been diagnosed with a sleep disorder, a recent
study found that over 70% of individuals with MS
screened positive for having at least one sleep
disorder although only 13% indicated having a
diagnosis of a sleep disorder.7 Although sleep
issues are common in individuals with MS, sleep
disorders are often undiagnosed and, therefore,
untreated in this population.
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Sleep disturbances may exacerbate or complicate
the management of MS-related symptoms. Sleep dis-
turbances have been associated with an increase
in perceived fatigue, depression, and anxiety in indi-
viduals with MS.5,8,9 Sleep issues can also impede
physical and cognitive functioning, participation in
activities, ability to work, and interpersonal relation-
ships.2,10–13 Furthermore, poor sleep quality has
been shown to be an independent predictor of
reduced quality of life in individuals with MS.10,11
Sleep disturbances also contribute to increased pain
perception,14 reduced learning of motor skills,15 and
can increase the risk for falls, accidents, and other
injuries.16 Sleep and circadian rhythm influence the
expression and modulation of the immune
system17,18 which may have particular implications
for individuals with MS. Sleep disruption has been
associated with a heightened proinflammatory state
including an increase in cytokines and oxidative
stress.17,18 As immune-mediated demyelination is a
well-established mechanism of MS,19 it is possible
that sleep disturbances contribute to the onset and/or
exacerbation of MS.20
Sleep diaries and actigraphy are common methods to
gather information about sleep duration and quality
over multiple nights of sleep. However, this data is
typically averaged across nights and the mean value
is reported. There is increased interest in the research
community to examine intraindividual variability
(IIV) or the extent to which sleep varies from
night to night.21 For example, someone could sleep
five hours on night 1, nine hours on night 2, and
seven hours on night 3 and the duration would be
averaged to seven hours/night. Another person could
sleep for seven hours all three nights and the dura-
tion would still be averaged to seven hours/night.
Reporting the mean excludes valuable information
about variablity across the nights. However, report-
ing sleep time variability alone does not provide
a complete picture. For example, someone could
sleep for five hours every night and another person
could sleep for eight hours every night. Both indi-
viduals would have no variability in their sleep, but
the first individual would be considered to have less
optimal sleep due to sleeping less than the recom-
mended seven or more hours of sleep for adults.22
Therefore, sleep needs to be considered in multiple
ways, including duration, perceived quality, and
variability.
IIV is also important to consider as it has been asso-
ciated with several health outcomes in adults, includ-
ing increased stress,23 negative affect,24 reduced
cognitive functioning,25 and symptoms of insom-
nia.26 However, it is unclear how IIV may contribute
to MS-related symptoms. Therefore, the purpose of
this secondary analysis was to determine if total
sleep time variability used in combination with
self-reported sleep quality would provide a clearer
picture of how sleep issues are associated to
MS-related symptoms, including fatigue, depression,
and anxiety.
Materials and methods
This is a secondary analysis of sleep data from
66 individuals collected via actigraphy as part of
studies to assess the association between sleep qual-
ity and cognitive function (although the actigraphy
data was not reported)2 and to assess the association
between sleep quality and fatigability.27 Both studies
included individuals with relapsing remitting or sec-
ondary progressive and a score of >24 on the
Mini Mental Status Examination (MMSE). The
study that assessed the association between sleep
quality and fatigability27 had additional inclusion
criteria of between ages of 18–60 years and the abil-
ity to ambulate with/without an assistive device.
Exclusion criteria for both studies were similar and
included self-report of known untreated sleep disor-
der (such as sleep apnea, insomnia, or restless
leg syndrome), a history of alcohol/drug abuse or
nervous system disorder other than MS, severe phys-
ical, neurological, or sensory impairments that
would prevent completion of testing, history of
learning disability or attention-deficit/hyperactivity
disorder, relapse and/or corticosteroid use within
four weeks of assessment, and uncorrected vision
loss that would interfere significantly with testing.
The study that assessed the association between sleep
quality and fatigability27 had additional exclusion cri-
teria that included acute ischemic cardiovascular
event or coronary artery bypass surgery less than
three months ago, and uncontrolled blood pressure
(BP) with medication (BP>190/110 mm Hg).
For both studies, participants completed in-person-
testing first and were then issued the actigraphnear
the end of the visit. Participants were given apo-
stage-paid envelope to return the actigraph.
Participants were recruited from the MS specialty
clinic at the University of Kansas Medical Center,
the Mid-America Chapter of National MS Society,
referral from consented subjects, area physicians, or
study personnel, and The University of Kansas
Medical Center Frontiers Research Participant
Registry. Participants were paid for participating in
the study to determine the association between sleep
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quality and cognitive function2 but not to participate
in the study to determine the association between
sleep quality and fatigability.27 Both studies were
approved and conducted in accordance with the
Institutional Review Board at the University of
Kansas Medical Center. Ninety-one participants par-
ticipated in the two prior studies, and 66 were
included in this secondary analysis. Twenty-five
people were excluded from this secondary analysis
because 12 did not have actigraphy data, three did
not complete the Pittsburgh Sleep Quality Index
(PSQI), three were determined to be outliers, and
seven had less than four nights of actigraphy data.
For both studies, individuals with MS wore an acti-
graph (Model wGT3X-BT, ActiGraph Corp.,
Pensacola, Florida, USA) on their wrist for seven
consecutive days. ActiLife software (version
6.11.8) was used to perform wear-time validation
and to analyze the sleep data using the Cole-
Kripke algorithm.28 Participants all had at least
four valid days of wear time which was defined as
at least 10 h of wear time per day.29 Participants also
completed the PSQI to assess self-report sleep qual-
ity over the past month. The PSQI yields a global
score that ranges from 0–21 and consists of seven
items including sleep quality, sleep latency, sleep
duration, sleep efficiency, sleep disturbances, use
of sleep medication, and daytime dysfunction.
These items are individually scored from 0–3, with
three representing the negative extreme. The item
scores are summed to provide a global score. Poor
sleepers have a score >5 as a cutoff global PSQI
score with sensitivity (89.6%) and specificity
(86.5%).30 Fatigue was assessed using the
Modified Fatigue Impact Scale (MFIS),31 which
consists of physical, cognitive, and psychosocial
functioning subscales. The MFIS is a 21-item scale
with a combination of nine items for physical status,
10 items for cognitive status, and two items for psy-
chosocial function status over the past four-weeks.
A five-point, Likert-type scale with anchors of never
(=0) and always (=4) deliver the total scores of these
items for the global score of the MFIS which ranges
from 0–84. Overall MFIS scores of 38 or above are
indicative of MS-related fatigue. State and trait anx-
iety was assessed using the State Trait Anxiety
Inventory (STAI).32 The STAI is a 40-item Likert
scale that measures two dimensions of “state” anxi-
ety (items 1–20) and “trait” anxiety (items 21–40).
Each item is rated on a four-point Likert-type scale.
Both State and Trait scales were established as uni-
dimensional measures. Scores of each scale range
from 20–80, with higher scores associated with
greater anxiety. Depression was assessed using the
Beck Depression Inventory-Fast Screen (BDI-FS).33
BDI-FS contains a seven-item self-report inventory
measuring the severity of depression symptoms in
adolescents and adults, and a high score indicates
severe depression symptoms. The scores on BDI-
FS range between 0–21. Demographic information
including age, sex, MS type, and disease duration
was also gathered.
Participants were divided into four groups based on
total sleep time (TST) variability gathered by acti-
graph and the PSQI. To describe TST variability,
the coefficient of variance (CV) was calculated for
each participant by dividing the sleep duration stan-
dard deviation by the sleep duration mean multiplied
by 100. Participants were divided into high or low
TST variability based on the mean CV for TST var-
iability which was 16.01%. Participants were also
divided based on perceived sleep quality. Individuals
with a score of >5 on PSQI were classified as having
poor sleep quality and those with 5 were classified
as having good sleep quality.30 Thus, participants
were distributed into four groups: good sleep quality
and low sleep variability group (Good Sleepers),
good sleep quality and high sleep variability group
(Moderate Sleepers), poor sleep quality and low
sleep variability group (Poor Reported Sleepers),
and poor sleep quality and high sleep variability
group (Bad Sleepers).
Data analysis was performed using SPSS (version
24; IBM SPSS Statistics Software). Chi-square
tests were used to determine group differences in
categorical demographic outcomes (sex, disease
type). Due to the unequal sample distribution,
Kruskal-Wallis Tests were used to compare out-
comes between the four groups. If the omnibus
Kruskal-Wallis Test was statistically significant,
Bonferroni tests were used to investigate which
groups were significantly different. The significance
level was set at 0.0125 to adjust for multiple
comparisons.
Results
Fourteen participants were in the Good Sleepers
group, five participants were in the Moderate
Sleepers group, 24 participants were in the Poor
Reported Sleepers group, and 23 participants were
in the Bad Sleepers group (Figure 1). Descriptive
results are reported in Table 1. As expected, the
Moderate Sleepers and Bad Sleepers had higher
TST variability than the Poor Reported Sleepers
and the Good Sleepers (Figure 2).
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Bad Sleepers had significant higher total fatigue
compared to Good Sleepers (p=0.003; Figure 3).
For the MFIS sub-scales, there was no significant
difference in physical fatigue between the groups
(Figure 4), but the Bad Sleepers had a significantly
higher level of cognitive fatigue and psychosocial
fatigue compared to the Good Sleepers (p=0.002,
Figure 5; and p=0.01, Figure 6, respectively). For
anxiety, the Poor Reported Sleepers had a signifi-
cantly higher level of state anxiety compared to
the Good Sleepers (p=0.004; Figure 7). Poor
Reported Sleepers and Bad Sleepers had a signifi-
cantly higher level of trait anxiety compared to the
Good Sleepers (p=0.001, p=0.007: Figure 8). The
Poor Reported Sleepers had a significantly higher
level of depression compared to Good Sleepers
(p=0.002; Figure 9).
Discussion
This is the first study to combine information about
sleep variability gathered using actigraphy with self-
report sleep quality to provide a clearer picture of
how sleep issues are associated with fatigue, anxiety,
and depression in individuals with MS. There were
significant differences between the Good Sleepers
and Bad Sleepers in overall fatigue, the fatigue sub-
scales of cognitive and psychosocial fatigue, and in
trait anxiety, and there were significant differences
in state and trait anxiety and depression between the
Good Sleepers and Poor Reported Sleepers. These
results may indicate a difference in factors contrib-
uting to sleep disturbances in individuals with self-
reported poor sleep quality with low versus high
sleep variability. Adding sleep variability in combi-
nation with self-reported sleep quality may be useful
Figure 1. Participants were divided into four groups based on the Pittsburgh Sleep Quality Index (PSQI) (5 Good Sleep
Quality; >5 Poor Sleep Quality) and on the mean of the coefficient of variance (CV) for total sleep time (TST) (<16.42
Low Sleep Variability; >16.01 High Sleep Variability).
Table 1. Demographic characteristics.
Good sleepers
(n¼14; 21.21%)
Moderate
sleepers
(n¼5; 7.57%)
Poor reported
sleepers
(n¼24; 36.36%)
Bad sleepers
(n¼23; 34.84%) p-Value
Age (years) 39.7813.85 43.48.84 51.049.77 50.8210.27 0.019
Sex (F/M) 11/3 4/1 21/3 21/2
Disease type (RR/SP) 13/1 4/1 16/8 22/1
Disease duration (years) 14.148.8 17.35.82 13.59.40 12.546.76 0.584
MMSE 28.421.91 28.801.64 28.501.61 29.131.01 0.622
PSQI 4.071.07 3.41.34 9.832.44 9.693.71 <0.0001
TST variability 11.193.19 28.848.89 10.083.91 22.334.70 <0.0001
Epworth 65.643.15 10.85.01 8.874.33 9.265.50 0.093
F: female; M: male; MMSE: Mini Mental Status Examination; PSQI: Pittsburgh Sleep Quality Index; RR: remitting–
relapsing; SD: standard deviation; SP: secondary progressive; TST: total sleep time.
Data is reported as (meanSD).
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Figure 2. Total sleep time variability across six nights for the four groups.
Figure 3. Total score of the Modified Fatigue Impact Scale (MFIS). Range of total score for MFIS is 0–84.
*<0.0125
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to better tailor interventions aimed at improving
sleep issues or these comorbid conditions.
In our study, 73% of the participants in this second-
ary analysis had poor sleep quality; 33% had poor
self-reported sleep quality with low sleep variability
and 40% had poor self-reported sleep quality with
high sleep variability. These findings provide addi-
tional evidence that poor sleep quality is common in
individuals with MS and supports findings from
prior studies that reported 47–70% of individuals
with MS experience poor sleep quality.1,2,10,34,35
Poor sleep quality has been associated with
increased fatigue, fatigability, depression, and anxi-
ety, and reduced physical and cognitive function and
quality of life2,27,36,37 as well as increased risk of
developing other chronic health conditions including
cardiovascular disease, obesity, and diabetes.16 Poor
sleep quality has also been associated with an
increased risk of an acute exacerbation of MS.20
This high prevalence of sleep issues in people with
MS and risk of health consequences warrants a con-
certed effort from the research and clinical commu-
nity in collaboration with individuals with MS and
other stakeholders to determine how to best address
sleep disturbances and factors contributing to sleep
Figure 4. Physical component of the Modified Fatigue Impact Scale (MFIS); range 0–36.
Figure 5. Cognitive component of the Modified Fatigue Impact Scale (MFIS); range 0–40.
*<0.0125
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disturbances and poorer sleep quality in individuals
with MS.
Not surprising was the low number of participants
(n=5; 7.57%) that had high self-reported sleep
quality combined with high sleep variability (the
Moderate Sleepers). It is presumed that individuals
with high sleep variability would generally not
consider their sleep quality to be good, and the
low number of participants in this category seem
to support this assumption. While the Moderate
Sleepers outcome scores generally fell between the
Good Sleepers and the Poor Reported Sleepers or
Bad Sleepers, there were no significant differences
in fatigue, anxiety, or depression between the
Moderate Sleepers and the other sleep groups. This
is possibly due to the limited number of participants
in the Moderate Sleepers group. It is also possible
that sleep variability is less important to the contri-
bution of overall sleep quality than perception of
sleep quality. This hypothesis is partially supported
by a post-hoc analysis consisting of dividing
Figure 6. Psychosocial component of the Modified Fatigue Impact Scale (MFIS); range 0–8.
*<0.0125
Figure 7. State component of the State Trait Anxiety Inventory (STAI); range 20–80.
*<0.0125
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participants into two groups based on TST
variability alone (high variability, n=28 vs low var-
iability, n=38) and examining group differences in
anxiety, depression, and fatigue between these two
groups. There were no statistically significant group
differences in anxiety, depression, and fatigue when
dividing the groups into high vs low variability,
suggesting that TST variability combined with self-
reported sleep quality is instrumental in considering
the association of anxiety, depression, and fatigue
with sleep quality.
Interestingly, there was variation in the factors that
were different between the Good Sleepers and Bad
Sleepers and between the Good Sleepers and Poor
Reported Sleepers, suggesting that different factors
may contribute to having self-reported poor sleep
quality with low TST variability (Poor Reported
Sleepers) and having self-report poor sleep quality
with high TST variability (Bad Sleepers). There was
a difference in state and trait anxiety and depression
between the Good Sleepers and Poor Reported
Sleepers whereas there was a difference in cognitive
Figure 8. Trait component of the State Trait Anxiety Inventory (STAI); range from 20–80.
*<0.0125
Figure 9. Beck Depression Inventory-Fast Screen (BDI-FS); range 0–21.
*<0.0125
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and psychological fatigue and trait anxiety between
the Good Sleepers and the Bad Sleepers. The Poor
Reported Sleepers had the highest score of state and
trait anxiety and depression of all four groups,
although not statistically different from the Bad
Sleepers. We cannot determine whether poor sleep
quality combined with low sleep variability contrib-
utes to anxiety and depression or if anxiety and
depression contribute to these sleep characteristics.
However, these results could indicate that state
and trait anxiety and depression are larger
influencing factors for people who have poor self-
reported sleep quality and low TST variability.
Evidence shows that sleep issues, depression, and
anxiety are highly interrelated,38,39 and prior studies
in people with MS have also shown poor sleep
quality to be associated with anxiety and depres-
sion.37,40,41 The association between sleep disturban-
ces, depression, and anxiety are likely due to several
mechanisms, including alterations in neurotransmit-
ter activity and hyperarousal of the areas of the brain
involved in emotional regulation.39,42 It is interest-
ing that fatigue was statistically higher only in the
Bad Sleepers. While we cannot determine the direc-
tion of this association, perhaps high sleep variabil-
ity contributes to fatigues in people with MS. Future
studies are needed to determine these assertions.
These results do support that fatigue, anxiety, and
depression should be assessed in individuals with
MS who have poor self-reported sleep quality, and
clinicians should consider that comorbid fatigue,
anxiety, and depression may have an impact on
self-reported sleep quality. Preliminary studies that
have used cognitive behavioral therapy for insomnia
offer promising results that treating insomnia symp-
toms may also improve fatigue, anxiety, and
depression.43,44
There are several limitations to this study. As this
was a secondary cross-sectional analysis, we are
unable to determine if fatigue, depression, and anx-
iety contribute to the development of poor sleep
quality or if poor sleep quality contribute to the
development of those comorbid conditions.
Longitudinal studies would be needed to determine
the direction of these associations. Also, although
individuals were excluded from participating in the
parent studies if they had a known untreated sleep
disorder, it is likely that at least some individuals
had an unknown sleep disorder as more than 70%
of individuals with MS screened positive for one or
more sleep disorders in a large national survey.7
Therefore, unknown and untreated sleep disorders
may have contributed to these results. Also, while
prior studies have assessed IIV using seven days/six
nights of data, other studies have used 14 days or
more worth of data to assess IIV.21 It remains
unclear how many nights of data is optimal for deter-
mining IIV. In addition, due to a large variation in
methods to assess IIV,21 there are no established
norms for sleep variability so it is difficult to deter-
mine if the data reported in this study is high or low.
Future studies are needed to ascertain which sleep
outcome is optimal to assess sleep variability (i.e.
total sleep time, sleep efficiency, sleep latency)
and to determine norms for sleep variability.
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